Standard Biotools: Pay

Standard Biotools paid its 3 named executives $14.5M in total in FY2025 (Dec). CEO Michael Egholm, Ph.D. was paid $8.8M of that.

Pay$100 in the stock at the end of FY21 → $33
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Michael Egholm, Ph.D.President, Chief Executive Officer, and Director
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)Not disclosed
FY2022 (Dec)Not disclosed
4 years
Alex KimChief Financial Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)Not disclosed
FY2022 (Dec)Not disclosed
4 years
Sean MackayChief Business Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)Not disclosed
FY2022 (Dec)Not disclosed
4 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 12 peers with pay on file was $7.0M. The CEO of Standard Biotools was paid $8.8M, 26% above the median.

  1. 1Halozyme Therapeutics
  2. 2Twist Bioscience
  3. 3Mirum Pharmaceuticals
  4. 4Adaptive Biotechnologies
  5. 5Standard Biotools
  6. 6Veracyte
  7. 7CareDx
  8. 8Castle Biosciences
  9. 910x Genomics
  10. 10Cytek Biosciences
  11. 11Pacific Biosciences Of California
  12. 12Orasure Technologies
  13. 13Cryoport
  14. 14AzentaNot disclosed
  15. 15Deciphera Pharmaceuticals, Inc.Not disclosed
  16. 16Gingko Bioworks Holdings, Inc.Not disclosed
  17. 17Guardant HealthNot disclosed
  18. 18Maravai Lifesciences HoldingsNot disclosed
  19. 19Mesa Laboratories Inc /Co/Not disclosed
  20. 20NeogenomicsNot disclosed
  21. 21QuanterixNot disclosed
  22. 22Surmodics, Inc.Not disclosed
  23. 23iRhythm Technologies, Inc.Not disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.